Xinchun Xu

821 citations
18 papers · 663 indexed · h-index 11
Topics
Ubiquitin and proteasome pathways (5 papers)Cancer-related Molecular Pathways (4 papers)Nanoparticle-Based Drug Delivery (3 papers)
Partner nations
ChinaUnited States

In The Last Decade

Xinchun Xu

17 papers receiving 658 citations

Peers

Xinchun Xu
Comparison fields: 5 of 79
  • Molecular Biology 419
  • Biomaterials 203
  • Biomedical Engineering 131
  • Cancer Research 78
  • Immunology 71
Replace Tiantian Tan with:
Tiantian Tan China
Ziwei Liao China
Bin Feng China
Timo Schomann Netherlands
Caifeng Deng China
Lina Guo China
Jingxiao Chen China
Francesco Mainini Italy
Xinchun Xu relative to Tiantian Tan China Tiantian Tan's profile →
Citations per field
00.5×8.2×
Tiantian Tan · 1×
Citations per year

Countries citing papers authored by Xinchun Xu

Since Specialization
Citations

This map shows the geographic impact of Xinchun Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinchun Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinchun Xu more than expected).

Fields of papers citing papers by Xinchun Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinchun Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinchun Xu. The network helps show where Xinchun Xu may publish in the future.

Co-authorship network of co-authors of Xinchun Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Xinchun Xu. A scholar is included among the top collaborators of Xinchun Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinchun Xu. Xinchun Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
#WorkIndexed citations
1 6
2 0
3 3
4 36
5 3
6 4
7 19
8 12
9 17
10 1
11
Deubiquitinase PSMD7 regulates cell fate and is associated with disease progression in breast cancer.
15
12 169
13 80
14 182
15 65
16 26
17
[Innovation of characteristic medicinal cupping devices].
1
18 24

About Xinchun Xu

Xinchun Xu is a scholar working on Complementary and alternative medicine, Biomaterials and Oncology, having authored 18 papers that have together received 663 indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (5 papers), Cancer-related Molecular Pathways (4 papers) and Nanoparticle-Based Drug Delivery (3 papers). The work is most often cited by research in Biomaterials (203 citations), Complementary and alternative medicine (63 citations) and Molecular Biology (419 citations). Xinchun Xu has collaborated with scholars based in China and United States. Frequent co-authors include Jianxin Wang, Jianming Liang, Jing Qin, Liang Pang, Yan Yuan, Ruixiang Li, Ying Zhu, Hongwei Ren, Yuwei He and Chao Hong. Their work appears in journals such as ACS Applied Materials & Interfaces, Journal of Controlled Release and British Journal Of Nutrition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026